Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Inclusion Criteria

• Patients diagnosed with a type 1 myocardial infarction within the previous 6 months.
• Subjects must be ≥65 years old, presenting with at least one of the following additional conditions:
• Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.
• Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.
• Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.
• Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
• Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.
• Age ≥ 75 years.
• Signing informed consent.

Exclusion Criteria

• Unable to sign informed consent.
• Contraindications to any of the components of the polypill.
• Living in a nursing home.
• Mental illness limiting the capacity of self-care.
• Participating in another clinical trial.
• Severe congestive heart failure (NYHA III-IV).
• Severe renal disease (Creatinine Clearance (CrCl) <30ml/min/1.73 m2).
• Need for oral anticoagulation at the time of randomization or planned in the future months.
• Any condition limiting life expectancy <2 years, including but not limited to active malignancy.
• Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).
• Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the prespecified timeframe).
• Do not agree to the filing, forwarding and use of his/ her pseudonymised data.